This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology 2017; 22(9): 514–20. doi: 10.1080/10245332.2017.1319115.FranchiniMVaglioSMaranoG, Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology2017; 22(9): 514–20. doi: 10.1080/10245332.2017.1319115.Open DOISearch in Google Scholar
Swindle JP, Xu Y, Mu Y, Solari PG. Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Curr Med Res Opin 2019; 35(8): 1433–40. doi: 10.1080/03007995.2019.1596437.SwindleJPXuYMuYSolariPG.Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Curr Med Res Opin2019; 35(8): 1433–40. doi: 10.1080/03007995.2019.1596437.Open DOISearch in Google Scholar
Hemlibra (emicizumab-kxwh) [package insert] [Internet]. South San Francisco, CA: Genentech, Inc.; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed February 2024).Hemlibra (emicizumab-kxwh) [package insert] [Internet]. South San Francisco, CA: Genentech, Inc.; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed February 2024).Search in Google Scholar
Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137(3): 410–9. doi: 10.1182/blood.2020006315.KnoeblPThalerJJilmaPQuehenbergerPGleixnerKSperrWR.Emicizumab for the treatment of acquired hemophilia A. Blood2021; 137(3): 410–9. doi: 10.1182/blood.2020006315.Open DOISearch in Google Scholar
Pishko AM, Doshi BS. Acquired hemophilia A: Current guidance and experience from clinical practice. J Blood Med 2022; 13: 255–65. doi: 10.2147/JBM.S284804.PishkoAMDoshiBS.Acquired hemophilia A: Current guidance and experience from clinical practice. J Blood Med2022; 13: 255–65. doi: 10.2147/JBM.S284804.Open DOISearch in Google Scholar
Mohinani A, Patel S, Tan V, et al. Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol 2023; 110(5): 470–9. doi: 10.1111/ejh.13930.MohinaniAPatelSTanV, Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol2023; 110(5): 470–9. doi: 10.1111/ejh.13930.Open DOISearch in Google Scholar
Tiede A, Kemkes-Matthes B, Knöbl P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 2021; 19(3): 637–44. doi: 10.1111/jth.15208.TiedeAKemkes-MatthesBKnöblP.Should emicizumab be used in patients with acquired hemophilia A?J Thromb Haemost2021; 19(3): 637–44. doi: 10.1111/jth.15208.Open DOISearch in Google Scholar
Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105(7): 1791–801. doi: 10.3324/haematol.2019.230771.TiedeACollinsPKnoeblPInternational recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica2020; 105(7): 1791–801. doi: 10.3324/haematol.2019.230771.Open DOISearch in Google Scholar
Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: 10.1111/hae.13618.OldenburgJMahlanguJNBujanW, The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia2019; 25(1): 33–44. doi: 10.1111/hae.13618.Open DOISearch in Google Scholar
Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–18. doi: 10.1111/hae.14183.MancusoMEMahlanguJSidonioR, Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia2020; 26(6): 1009–18. doi: 10.1111/hae.14183.Open DOISearch in Google Scholar
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–22. doi: 10.1056/NEJMoa1803550.MahlanguJOldenburgJPaz-PrielI, Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med2018; 379(9): 811–22. doi: 10.1056/NEJMoa1803550.Open DOISearch in Google Scholar
Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): e295–305. doi: 10.1016/S2352-3026(19)30054-7.PipeSWShimaMLehleM, Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol2019; 6(6): e295–305. doi: 10.1016/S2352-3026(19)30054-7.Open DOISearch in Google Scholar
Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost 2019; 17(9): 1470–7. doi: 10.1111/jth.14491.LevyGGAsikaniusEKueblerP, Benchikh El FegounSEsbjergSSeremetisS.Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost2019; 17(9): 1470–7. doi: 10.1111/jth.14491.Open DOISearch in Google Scholar
Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost 2020; 18(4): 825–33. doi: 10.1111/jth.14746.TakeyamaMNogamiKMatsumotoTNoguchi-SasakiMKitazawaTShimaM.An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost2020; 18(4): 825–33. doi: 10.1111/jth.14746.Open DOISearch in Google Scholar
Pasca S, Zanon E, Mannucci PM, Peyvandi F. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus 2023; 21(6): 549–56. doi: 10.2450/2023.0247-22.PascaSZanonEMannucciPMPeyvandiF.Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus2023; 21(6): 549–56. doi: 10.2450/2023.0247-22.Open DOISearch in Google Scholar
Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 2023; 21(3): 534–45. doi: 10.1016/j.jtha.2022.10.004.ShimaMAmanoKOgawaY, A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost2023; 21(3): 534–45. doi: 10.1016/j.jtha.2022.10.004.Open DOISearch in Google Scholar
Hess KJ, Patel P, Joshi AM, Kotkiewicz A. Utilization of emicizumab in acquired factor VIII deficiency. Am J Case Rep 2020; 21: e922326. doi: 10.12659/AJCR.922326.HessKJPatelPJoshiAMKotkiewiczA.Utilization of emicizumab in acquired factor VIII deficiency. Am J Case Rep2020; 21: e922326. doi: 10.12659/AJCR.922326.Open DOISearch in Google Scholar
Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 2019; 3(3): 420–3. doi: 10.1002/rth2.12201.DaneKELindsleyJPStreiffMBMoliternoARKhalidMKShanbhagS.Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost2019; 3(3): 420–3. doi: 10.1002/rth2.12201.Open DOISearch in Google Scholar
Chen SL, Ellsworth P, Kasthuri RS, Moll S, Ma AD, Key NS. Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. Haemophilia 2021; 27(4): e585–8. doi: 10.1111/hae.14335.ChenSLEllsworthPKasthuriRSMollSMaADKeyNS.Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. Haemophilia2021; 27(4): e585–8. doi: 10.1111/hae.14335.Open DOISearch in Google Scholar
Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46(2): 121–3. doi: 10.1159/000497287.MöhnlePPekrulISpannaglMSturmASinghDDechantC.Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother2019; 46(2): 121–3. doi: 10.1159/000497287.Open DOISearch in Google Scholar
Yates SG, Webb CB, Sarode R, Ibrahim IF, Shen YMP. Utilization of emicizumab in acquired hemophilia A: a case report. Transfus Apher Sci 2022; 61(6): 103457. doi: 10.1016/j. transci.2022.103457.YatesSGWebbCBSarodeRIbrahimIFShenYMP.Utilization of emicizumab in acquired hemophilia A: a case report. Transfus Apher Sci2022; 61(6): 103457. doi: 10.1016/j. transci.2022.103457.Open DOISearch in Google Scholar
Escobar M, Aboshady I, Montanez N. Prophylactic potential of standard and modified emicizumab prophylaxis in 2 patients with acquired hemophilia: a case report [abstract]. Res Pract Thromb Haemost 2020; 4 (Suppl 1). Available from https://abstracts.isth.org/abstract/prophylactic-potential-of-standard-and-modified-emicizumab-prophylaxis-in-2-patients-with-acquired-hemophilia-a-case-report/ (accessed February 2024).EscobarMAboshadyIMontanezN.Prophylactic potential of standard and modified emicizumab prophylaxis in 2 patients with acquired hemophilia: a case report [abstract]. Res Pract Thromb Haemost2020; 4 (Suppl 1). Available from https://abstracts.isth.org/abstract/prophylactic-potential-of-standard-and-modified-emicizumab-prophylaxis-in-2-patients-with-acquired-hemophilia-a-case-report/ (accessed February 2024).Search in Google Scholar
Gelbenegger G, Traby L, Rahimi N, Knöbl P. Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis. Br J Clin Pharmacol 2023; 89(2): 908–13. doi: 10.1111/bcp.15598.GelbeneggerGTrabyLRahimiNKnöblPManagement of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis. Br J Clin Pharmacol2023; 89(2): 908–13. doi: 10.1111/bcp.15598.Open DOISearch in Google Scholar
Al-Banaa K, Alhillan A, Hawa F, et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 2019; 20: 1046–8. doi: 10.12659/AJCR.916783.Al-BanaaKAlhillanAHawaF, Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep2019; 20: 1046–8. doi: 10.12659/AJCR.916783.Open DOISearch in Google Scholar
Latef TJ, Bhardwaj P, Bilal M. Refractory acquired haemophilia A in a patient with HIV treated with Emicizumab. Blood Coagul Fibrinolysis 2022; 33(2): 138–40. doi: 10.1097/MBC.0000000000001118.LatefTJBhardwajPBilalM.Refractory acquired haemophilia A in a patient with HIV treated with Emicizumab. Blood Coagul Fibrinolysis2022; 33(2): 138–40. doi: 10.1097/MBC.0000000000001118.Open DOISearch in Google Scholar
Flommersfeld S, Slonka J, Bieberle I, Stockschläder A, Kemkes-Matthes B, Sachs UJ. Successful control of bleeding with emicizumab in aquired haemophilia A: a case report. Poster I P01 Acquired Coagulation Disorders/Thrombocytopenias [abstract]. Hämostaseologie 2019; 39(S01). doi: 10.1055/s-0039-1680166.FlommersfeldSSlonkaJBieberleIStockschläderAKemkes-MatthesBSachsUJ.Successful control of bleeding with emicizumab in aquired haemophilia A: a case report. Poster I P01 Acquired Coagulation Disorders/Thrombocytopenias [abstract]. Hämostaseologie2019; 39(S01). doi: 10.1055/s-0039-1680166.Open DOISearch in Google Scholar
Hansenne A, Hermans C. Emicizumab in acquired haemophilia A: about two clinical cases and literature review. Ther Adv Hematol 2021; 12: 20406207211038193. doi: 10.1177/20406207211038193.HansenneAHermansC.Emicizumab in acquired haemophilia A: about two clinical cases and literature review. Ther Adv Hematol2021; 12: 20406207211038193. doi: 10.1177/20406207211038193.Open DOISearch in Google Scholar
Crossette-Thambiah C, Arachchillage D, Laffan M. Postpartum acquired haemophilia A in the COVID era – building the case for emicizumab? [abstract]. Available from https://abstracts.isth.org/abstract/post-partum-acquired-haemophilia-a-in-the-covid-era-building-the-case-for-emicizumab/ (accessed February 2024).Crossette-ThambiahCArachchillageDLaffanM.Postpartum acquired haemophilia A in the COVID era – building the case for emicizumab? [abstract]. Available from https://abstracts.isth.org/abstract/post-partum-acquired-haemophilia-a-in-the-covid-era-building-the-case-for-emicizumab/ (accessed February 2024).Search in Google Scholar
Happaerts M, Vanassche T. Acquired hemophilia following COVID-19 vaccination: Case report and review of literature. Res Pract Thromb Haemost 2022; 6(6): e12785. doi: 10.1002/rth2.12785.HappaertsMVanasscheT.Acquired hemophilia following COVID-19 vaccination: Case report and review of literature. Res Pract Thromb Haemost2022; 6(6): e12785. doi: 10.1002/rth2.12785.Open DOISearch in Google Scholar
Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv 2022; 6(24): 6140–50. doi: 10.1182/bloodadvances.2022007458.Kruse-JarresRPeyvandiFOldenburgJ, Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv2022; 6(24): 6140–50. doi: 10.1182/bloodadvances.2022007458.Open DOISearch in Google Scholar